Investigating the role of long noncoding RNAs in acute myeloid leukemia
The role of long noncoding RNAs in acute myeloid leukemia
This study is looking at how certain RNA molecules affect the growth and treatment of acute myeloid leukemia (AML), with the goal of finding new ways to help patients, especially those whose cancer has come back.
Quick facts
| Grant type | R21 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Virginia NIH-funded |
| Lab location | 1 site (Charlottesville, United States) |
| Project ID | NIH-10990156 on NIH RePORTER |
What this research studies
This research focuses on understanding how long noncoding RNAs influence the development and treatment of acute myeloid leukemia (AML), a serious blood cancer. The team aims to identify molecular regulators that interact with cancer-associated transcription factors, which are crucial for the disease's progression and resistance to treatment. By studying these RNA molecules, the researchers hope to uncover new therapeutic strategies that could improve patient outcomes, especially for those with relapsed AML. The approach involves analyzing the effects of specific noncoding RNAs on myeloid cell differentiation and growth inhibition.
Who could benefit from this research
Good fit: Ideal candidates for this research are individuals diagnosed with acute myeloid leukemia, particularly those experiencing relapse or resistance to standard therapies.
Not a fit: Patients with other types of blood cancers or those who are not diagnosed with acute myeloid leukemia may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to new treatment options that overcome drug resistance in AML patients.
How similar studies have performed: Previous research has shown promise in targeting noncoding RNAs for cancer treatment, suggesting that this approach could yield significant advancements in AML therapy.
Where this research is happening
Charlottesville, United States
- University of Virginia — Charlottesville, United States (Active)
Researchers
- Principal investigator: Trinh, Bon Q — University of Virginia
- Study coordinator: Trinh, Bon Q
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.